Can MS Be Mistaken for Rheumatoid Arthritis?

Multiple sclerosis and rheumatoid arthritis are distinct diseases affecting different body systems, yet they get confused with each other more often than most people realize. About 40% of people eventually diagnosed with MS report having been previously misdiagnosed with something else, and patients with a personal history of autoimmune conditions are significantly more likely to receive a wrong MS label in the first place. The overlap between these two conditions runs deeper than shared fatigue and stiffness, touching on pain patterns, blood test results, imaging findings, and even shared genetic risk factors.

Where the Symptom Lines Blur

The most intuitive reason MS might be mistaken for RA is pain. MS is often thought of as a disease of numbness, vision problems, and difficulty walking, but musculoskeletal pain is surprisingly common. In one cross-sectional study of MS patients, roughly 88% were experiencing pain at the time they were surveyed. The most frequently affected areas were the knees, wrists, and neck, which are also among the joints most commonly involved in rheumatoid arthritis.¹ A clinician seeing a woman in her thirties or forties with bilateral wrist and knee pain, fatigue, and some morning stiffness could easily start down the rheumatology path before neurological symptoms become obvious.

The type of pain matters, too. A nationwide survey of over 800 adults with both chronic pain and MS found that the largest proportion, about 41%, had nociceptive pain, which is the same kind of deep aching that inflamed joints produce. Neuropathic pain, the tingling and burning more typically associated with nerve damage, accounted for only about 9% of cases on its own. The rest had mixed or nociplastic pain patterns.² When the dominant pain experience in an MS patient feels like arthritis rather than nerve damage, the diagnostic waters get murky early on.

Fatigue compounds the confusion. Both MS and RA produce profound, disabling fatigue that goes well beyond normal tiredness. In both conditions, fatigue can be the single most debilitating symptom, and patients frequently describe it in near-identical terms. Neither disease “owns” fatigue as a diagnostic clue, so its presence rarely tips the scales in one direction.

When Rheumatoid Arthritis Looks Neurological

The confusion does not only run in one direction. RA can occasionally produce symptoms that look strikingly like MS. One of the best-documented examples is cervical myelopathy, a condition where the spinal cord in the neck becomes compressed. In RA, chronic inflammation can destabilize the upper cervical spine, allowing the top vertebrae to shift and press on the spinal cord. This occurs in roughly 2.5% of patients who have had RA for more than 14 years.³

The resulting symptoms can include weakness in the arms and legs, difficulty with balance and coordination, changes in sensation, and problems with bladder control. Those are also hallmark symptoms of MS. A patient with long-standing RA who develops gradual limb weakness and numbness might trigger a workup for MS before anyone thinks to image the upper spine for instability. The key difference is the mechanism: in MS, the immune system attacks the myelin coating around nerves in the brain and spinal cord; in RA cervical myelopathy, inflamed tissue and bone shifts physically squeeze the cord. But from the patient’s perspective, the symptoms can feel identical.

Blood Tests That Muddy the Picture

You might expect that blood work would quickly sort things out. RA has well-known markers like rheumatoid factor and anti-CCP antibodies, and MS has its own diagnostic toolkit. But autoimmune conditions have a frustrating tendency to produce overlapping antibody results, especially in early or mild disease.

A study from the Vienna MS database found that about 11% of MS patients had positive antinuclear antibody (ANA) results.⁴ ANAs are not specific to any single disease, but they are part of the standard autoimmune workup, and a positive result in someone with joint pain and fatigue can push a clinician toward a rheumatologic diagnosis. An MS patient with a mildly positive ANA, bilateral wrist pain, and fatigue could easily meet informal screening criteria for further rheumatology evaluation before anyone orders a brain MRI.

Conversely, early RA does not always produce clear-cut antibody results. Up to a third of people with RA are seronegative, meaning their rheumatoid factor and anti-CCP tests come back normal. When someone has joint pain, fatigue, and nonspecific inflammation markers but no definitive RA antibodies, the diagnosis can stall in an ambiguous zone where MS and several other autoimmune conditions remain on the table.

MRI Findings and Their Limits

Brain MRI is often considered the gold standard for identifying MS, but the reality is less clean-cut than textbooks suggest. White matter lesions on brain MRI, while regarded as a hallmark of MS, are a common radiological finding whose pattern can overlap with other inflammatory conditions, including those tied to rheumatic diseases.⁵ Small, scattered white matter spots can appear in people with RA, lupus, Sjögren’s syndrome, or even in healthy people as they age. No fully specific diagnostic test currently exists to distinguish MS from every other inflammatory brain condition based on imaging alone.

In a study of patients referred to a specialized MS center in Catalonia, about 7% of those who arrived with an “established MS” diagnosis turned out to have been misdiagnosed. In every one of those cases, MRI had shown multifocal white matter lesions that were ultimately deemed nonspecific or not suggestive of MS on closer review. Patients who were misdiagnosed were significantly more likely to have a personal history of other autoimmune conditions.⁶ In other words, having RA or another autoimmune disease on your chart may actually increase the chance of a false MS label, because clinicians already have autoimmunity on their radar and may interpret ambiguous MRI spots through that lens.

Experienced neuroradiologists look for specific patterns: lesions touching the ventricles, lesions in the corpus callosum, lesions in the spinal cord, and evidence that lesions developed at different times. These patterns help distinguish MS from the nonspecific white matter changes that many autoimmune conditions can produce. But the distinction requires expertise, and referral-center re-reads sometimes reach different conclusions than the original interpretation.

Cerebrospinal Fluid Testing

A lumbar puncture can add diagnostic clarity that blood tests and MRI alone cannot provide. In MS, cerebrospinal fluid often contains oligoclonal bands, which are specific patterns of antibodies produced within the central nervous system. Their presence strongly supports an MS diagnosis, but their absence does not rule it out, and their occasional presence in other conditions keeps things complicated.

A study examining matched oligoclonal band patterns found that systemic rheumatologic diseases accounted for a small fraction of cases in their inflammatory neurological disease cohort.⁷ Infections and autoimmune encephalitis were far more common mimics. Still, the fact that rheumatologic conditions appear in the differential at all underscores that no single test draws a bright line between these disease categories. Diagnosis in this space is pattern-based, relying on the combination of clinical presentation, imaging, blood work, and spinal fluid rather than any one definitive marker.

When RA Drugs Trigger Demyelination

One of the more alarming intersections between MS and RA involves treatment rather than diagnosis. Biologic drugs called TNF inhibitors, widely used for RA and other inflammatory conditions, have been associated with demyelinating events that look exactly like MS. These events can include optic neuritis, limb weakness, sensory changes, and new white matter lesions on MRI.

A large study from the British biologics registry tracked over 13,000 RA patients starting anti-TNF therapy and identified 35 who developed demyelinating events, yielding a raw incidence of about 20 per 100,000 patient-years. When the analysis was limited to definite or probable cases, the rate did not clearly exceed what would be expected in the general population.⁸ That ambiguity is the crux of a long-running debate: do anti-TNF drugs cause MS-like episodes, or do they unmask MS that was already developing in someone who happened to also have RA?

Either way, the clinical scenario creates real confusion. A patient with established RA who develops neurological symptoms while on a biologic faces a diagnostic puzzle: Is this drug-related demyelination that will resolve when the medication stops? Is this genuine MS emerging independently? Or is this something else entirely? The answer shapes treatment decisions dramatically, since TNF inhibitors can worsen true MS. Clinicians generally stop the biologic and wait to see whether symptoms resolve, then proceed with a full MS workup if they do not.

The Two Conditions Can Coexist

Adding another layer of complexity, MS and RA are not mutually exclusive. Population-level data from a nationwide cohort study showed an increased incidence of RA among people with MS, suggesting the two conditions co-occur more often than chance alone would predict.⁹ Shared genetic risk factors likely contribute: certain gene variants, including those in the tyrosine kinase 2 and MHC class II transactivator pathways, have been linked to susceptibility for both diseases.

When someone genuinely has both conditions, the diagnostic picture becomes even harder to untangle. Joint pain might be RA, or it might be MS-related musculoskeletal pain. A new MRI lesion might represent MS progression, or it could be a coincidental nonspecific finding. Fatigue could stem from either condition, or from both simultaneously. Clinicians managing these patients typically need both a neurologist and a rheumatologist working in coordination, and even then, attributing individual symptoms to one disease versus the other can be guesswork.

Sjögren’s Syndrome as a Complicating Bridge

Sjögren’s syndrome deserves special mention because it frequently overlaps with both MS and RA and can act as a diagnostic bridge that links the two. Sjögren’s is an autoimmune disease primarily known for dry eyes and dry mouth, but it can also affect the nervous system. Primary Sjögren’s syndrome has been associated with MS, raising questions about shared immunologic mechanisms between the two conditions.¹⁰ At the same time, secondary Sjögren’s commonly accompanies RA.

A patient with undiagnosed Sjögren’s who presents with neurological symptoms might be worked up for MS, while one who presents with joint symptoms might be worked up for RA. Both evaluations could lead to a partially correct diagnosis that misses the underlying Sjögren’s, or to a misdiagnosis that sends the patient down the wrong treatment pathway entirely. The neurological manifestations of Sjögren’s can include white matter lesions on MRI, further muddying the distinction from MS. Clinicians who are aware of this three-way overlap tend to order Sjögren’s-specific antibody tests (anti-SSA and anti-SSB) as part of any ambiguous autoimmune workup, but this is not always done in the early stages of investigation.

How Diagnostic Delays Play Out

The practical consequence of all this overlap is delayed diagnosis. In a registry-based study of MS patients, about 40% reported having been misdiagnosed before eventually receiving their MS diagnosis. Among those who recalled specific prior misdiagnoses, roughly 58% had been given an alternative neurological diagnosis and about 25% had received a psychiatric one. The average number of prior misdiagnoses was 1.6, and having been previously misdiagnosed was associated with a significantly longer delay from symptom onset to correct diagnosis.¹¹

While RA was not singled out as the most common misdiagnosis in that study, the broader point holds: autoimmune conditions with overlapping symptoms routinely send patients on long diagnostic detours. Someone whose MS first manifests as joint pain and fatigue, without obvious neurological red flags, might spend months or even years being evaluated and treated for a rheumatic condition before a neurological symptom finally prompts a brain MRI.

Delays matter because both diseases benefit from early treatment. In MS, starting disease-modifying therapy early can significantly reduce the accumulation of disability. In RA, early aggressive treatment helps prevent irreversible joint damage. A misdiagnosis in either direction means the wrong disease is being treated while the right one progresses unchecked.

Practical Signals That Should Prompt a Second Look

If you have been diagnosed with RA but certain symptoms do not fit the typical pattern, there are specific red flags that warrant asking about MS. Vision changes, especially episodes of blurry or lost vision in one eye (optic neuritis), are uncommon in RA but classic for MS. Numbness or tingling that follows a nerve-distribution pattern rather than a joint-distribution pattern is another important clue. Bladder urgency or incontinence that develops alongside joint symptoms is unusual for RA alone. And Lhermitte’s sign, an electric-shock sensation running down the spine when you bend your neck, is highly suggestive of a spinal cord problem rather than joint disease.

Going the other direction, if you carry an MS diagnosis but have persistent, symmetrical joint swelling, especially in the small joints of the hands and feet with visible puffiness and warmth, that pattern points toward RA rather than the musculoskeletal pain that MS alone typically produces. MS pain tends to be more diffuse and harder to localize, while RA inflammation produces objectively swollen joints that a clinician can see and feel. Morning stiffness lasting more than an hour is another RA hallmark that does not fit a pure MS picture.

Neither set of symptoms is absolute proof, but each should prompt the question of whether a second opinion from the other specialty is warranted. The patients who navigate this overlap most successfully tend to be those who advocate for cross-specialty evaluation when their symptoms do not neatly fit one box.

Why Both Conditions Tend to Affect the Same People

Both MS and RA disproportionately affect women, with female-to-male ratios of roughly 3:1 for MS and 2-3:1 for RA. Both conditions most commonly appear during the working years, between the late twenties and early fifties. This demographic overlap means the patient population being evaluated for one condition heavily overlaps with the population at risk for the other. A 35-year-old woman presenting with fatigue and pain fits the demographic profile for both diseases equally well, giving clinicians no easy shortcut based on age or sex.

The shared genetic susceptibility identified in cohort studies adds biological plausibility to the demographic overlap. Variants in immune-regulation genes that increase risk for one condition often increase risk for the other, which is why autoimmune diseases tend to cluster in families and sometimes in the same individual. If you have a first-degree relative with RA, your risk of developing MS is slightly elevated too, and vice versa. This clustering means that a personal or family history of autoimmunity, while often treated as a diagnostic clue pointing toward “some autoimmune condition,” does not narrow the field as much as clinicians might hope.